Literature DB >> 3191936

Phenotyping polymorphic drug metabolism in the French Caucasian population.

E Jacqz1, H Dulac, H Mathieu.   

Abstract

Because of the large interethnic differences in the incidence of poor metabolizer phenotypes, French Caucasians have been studied for two independent polymorphisms, debrisoquine/dextromethorphan and mephenytoin metabolism. One hundred and thirty-two unrelated French Caucasians were phenotyped using oral doses of dextromethorphan 20 mg and mephenytoin 100 mg. Individual dextrorphan excretion over 8 h and the dextromethorphan/dextrorphan metabolic ratio were calculated. Extensive metabolizers were taken as subjects with a high dextrorphan output (15.56 mumol/8 h) and a low metabolic ratio (0.0023), and poor metabolizers were those with a low dextrorphan output (0.39 mumol/8 h) and a high metabolic ratio (7.00). Individual 4-hydroxymephenytoin excretion and mephenytoin hydroxylation indices were also determined. Extensive metabolizers eliminated large amounts of 4 hydroxymephenytoin (133.2 mumol/8 h) and had a hydroxylation index of 1.99, and poor metabolizers, because of impaired mephenytoin metabolism, had a high hydroxylation index (277). The incidence of the poor metabolizer phenotype was 3% for dextromethorphan (95% confidence limits 0.5%-8.5%) and 6% for mephenytoin (95% confidence limits 2%-12.5%).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191936     DOI: 10.1007/bf00609247

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

Authors:  A Küpfer; B Schmid; R Preisig; G Pfaff
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

Review 2.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

3.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  The urinary excretion of dextromethorphan and three metabolites in dogs and humans.

Authors:  J W Barnhart
Journal:  Toxicol Appl Pharmacol       Date:  1980-08       Impact factor: 4.219

6.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

7.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.

Authors:  N M Woolhouse; B Andoh; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

8.  Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography.

Authors:  Y H Park; M P Kullberg; O N Hinsvark
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

Review 9.  Contribution of environmental factors to variability in human drug metabolism.

Authors:  C T Dollery; H S Fraser; J C Mucklow; C J Bulpitt
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

10.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

View more
  20 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

3.  Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population.

Authors:  J P Frèche; S Dragacci; A M Petit; J P Siest; M M Galteau; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

5.  Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis.

Authors:  E Jacqz-Aigrain; J Laurent; F Alvarez
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 6.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

7.  Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.

Authors:  Imad Zalloum; Nancy Hakooz; Tawfiq Arafat
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.